Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice
M Bosman, DN Krüger, K Favere, GRY De Meyer… - Plos one, 2023 - journals.plos.org
Apart from cardiotoxicity, the chemotherapeutic agent doxorubicin (DOX) provokes acute
and long-term vascular toxicity. Dexrazoxane (DEXRA) is an effective drug for treatment of …
and long-term vascular toxicity. Dexrazoxane (DEXRA) is an effective drug for treatment of …
4-Deoxy-ε-Pyrromycinone: A Promising Drug/Lead Compound to Treat Tumors
J Zhang, X Sang, Y Yuan, J Shen, Y Fang… - Drug Design …, 2024 - Taylor & Francis
Background Anthraquinone drugs are widely used in the treatment of tumors. However,
multidrug resistance and severe cardiac toxicity limit its use, which have led to the discovery …
multidrug resistance and severe cardiac toxicity limit its use, which have led to the discovery …
Knockdown of NR4A1 alleviates doxorubicin-induced cardiotoxicity through inhibiting the activation of the NLRP3 inflammasome
H Hu, Z Zhong, L Meng, J Chen, Z Yu, K Lu - Biochemical and Biophysical …, 2024 - Elsevier
Doxorubicin (DOX) is a widely used antitumor drug, but its clinical applicability is hampered
by the unfortunate side effect of DOX-induced cardiotoxicity (DIC). In our current study, we …
by the unfortunate side effect of DOX-induced cardiotoxicity (DIC). In our current study, we …
Thoracic aorta injury detected by 4D flow MRI predicts subsequent main adverse cardiovascular events in breast cancer patients receiving anthracyclines: A …
H Shen, W Zhou, Y Peng, X Li, D Liu, X Wang… - Magnetic Resonance …, 2024 - Elsevier
Purpose To investigate longitudinal thoracic aorta injury using 3-dimensional phase-contrast
magnetic resonance imaging (4D flow MRI) parameters and to evaluate their value for …
magnetic resonance imaging (4D flow MRI) parameters and to evaluate their value for …
[HTML][HTML] Characterization of systolic and diastolic function, alongside proteomic profiling, in doxorubicin-induced cardiovascular toxicity in mice
DN Krüger, M Bosman… - Cardio …, 2024 - cardiooncologyjournal …
The anthracycline doxorubicin (DOX) is a highly effective anticancer agent, especially in
breast cancer and lymphoma. However, DOX can cause cancer therapy-related …
breast cancer and lymphoma. However, DOX can cause cancer therapy-related …
Irisin links Claudin-5 preservation and Mfn2-mediated mitochondrial dynamics to resist doxorubicin-induced cardiac endothelial damage
J He, L Hou, Q Liu, R Zhou - Biochemical and Biophysical Research …, 2024 - Elsevier
Irisin is protective in the cardiac microenvironment and can resist doxorubicin-induced
cardiotoxicity. The purpose of this study was to investigate the connection between Irisin …
cardiotoxicity. The purpose of this study was to investigate the connection between Irisin …
Intravenous Thrombolysis for Pediatric Ischemic Stroke Secondary to Cancer Therapy-related Cardiac Dysfunction: A Case Report
F Eto, T Nezu, H Sakahara, Y Yamamoto, S Aoki… - Internal …, 2024 - jstage.jst.go.jp
An 11-year-old boy developed cardioembolic stroke (CES) and cancer therapy-related
cardiac dysfunction (CTRCD). He originally developed Ewing sarcoma and was treated with …
cardiac dysfunction (CTRCD). He originally developed Ewing sarcoma and was treated with …